VAXART, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.704 USD | -0.80% |
|
-16.42% | +22.91% |
| Mar. 14 | Vaxart, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Mar. 14 | Transcript : Vaxart, Inc., 2023 Earnings Call, Mar 14, 2024 |
Financials (USD)
| Sales 2024 * | 14.73M | Sales 2025 * | 23.1M | Capitalization | 126M |
|---|---|---|---|---|---|
| Net income 2024 * | -77M | Net income 2025 * | -80M | EV / Sales 2024 * | 8.52 x |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 5.43 x |
| P/E ratio 2024 * |
-1.57
x | P/E ratio 2025 * |
-1.8
x | Employees | 109 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.75% |
More Fundamentals
* Assessed data
More news
Latest transcript on Vaxart, Inc.
More recommendations
More press releases
More news
| 1 day | -4.79% | ||
| 1 week | -18.06% | ||
| Current month | -45.41% | ||
| 1 month | -43.67% | ||
| 3 months | -11.72% | ||
| 6 months | +8.85% | ||
| Current year | +23.90% |
1 week
0.70
0.86
1 month
0.701.41
Current year
0.551.54
1 year
0.531.59
3 years
0.5311.11
5 years
0.2524.90
10 years
0.2524.90
| Managers | Title | Age | Since |
|---|---|---|---|
Sean Tucker
FOU | Founder | - | 03-12-31 |
Phillip Eric Lee
DFI | Director of Finance/CFO | 37 | 22-12-18 |
Michael Finney
CHM | Chairman | 65 | 07-06-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Robert Yedid
BRD | Director/Board Member | 66 | 19-10-24 |
Elaine Heron
BRD | Director/Board Member | 76 | 22-08-24 |
Michael Finney
CHM | Chairman | 65 | 07-06-30 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 2 M€ | -.--% | ||
| 0.01% | 9 M€ | -.--% | - | |
| 0.00% | 9 M€ | +6.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-25 | 0.704 | -0.80% | 123 363 |
| 24-04-24 | 0.7097 | -4.79% | 1,463,800 |
| 24-04-23 | 0.7454 | -2.24% | 1,586,300 |
| 24-04-22 | 0.7625 | +0.91% | 937,280 |
| 24-04-19 | 0.7556 | -10.29% | 1,913,793 |
Delayed Quote Nasdaq, April 24, 2024 at 04:00 pm EDT
More quotes
Vaxart, Inc. is a clinical-stage biotechnology company that is primarily focused on the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) proprietary oral vaccine platform. Its vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Its development programs include pill vaccines designed to protect against norovirus (cause for acute gastroenteritis), coronavirus, including SARS-CoV-2 (COVID-19)), and influenza. In addition, it has generated preclinical data for its therapeutic vaccine candidate targeting cervical cancer and dysplasia caused by human papillomavirus. The Company's platform technology employs a vector-based approach and consists of various components, such as a vector (adenovirus type 5 (Ad5); an antigen (Ad5 DNA); an adjuvant (Toll-like receptor 3 (TLR3)), and its proprietary enteric-coated tablet.
Calendar
2024-05-07
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
0.7097
USD
Average target price
5
USD
Spread / Average Target
+604.52%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +23.90% | 126M | |
| -1.51% | 104B | |
| +3.22% | 97.42B | |
| +1.86% | 22.2B | |
| -16.53% | 21.23B | |
| -8.49% | 18.33B | |
| -42.33% | 16.35B | |
| -20.09% | 15.06B | |
| +5.47% | 13.98B | |
| +28.85% | 11.66B |
- Stock Market
- Equities
- VXRT Stock
